Global Subcutaneously Injected PD-L1 Antibody Market Size, Status and Forecast 2026-2032

Subcutaneously Injected PD-L1 Antibody Market

The global Subcutaneously Injected PD-L1 Antibody market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

PD-L1 antibody is a type of drug in tumor immunotherapy, which reduces immune suppression by binding to PD-L1 and blocking the binding between PD-1 and PD-L1, allowing T cells to exert anticancer effects. At present, PD-L1 antibodies on the market are generally administered intravenously, while subcutaneous injection can avoid various adverse reactions of intravenous infusion and improve patients' medical experience and quality of life.

The North American market for Subcutaneously Injected PD-L1 Antibody is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Subcutaneously Injected PD-L1 Antibody is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Subcutaneously Injected PD-L1 Antibody in Rectal and Renal Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Subcutaneously Injected PD-L1 Antibody include Roche, Alphamab Oncology, Bristol Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report focuses on the global Subcutaneously Injected PD-L1 Antibody status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Subcutaneously Injected PD-L1 Antibody development in different regions.

It segments the global Subcutaneously Injected PD-L1 Antibody market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Subcutaneously Injected PD-L1 Antibody manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Subcutaneously Injected PD-L1 Antibody Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Subcutaneously Injected PD-L1 Antibody Market Size Growth Rate by Type (2026-2032)

1.2.2 Add Hyaluronidase

1.2.3 No Hyaluronidase

1.3 Market by Application

1.3.1 Global Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)

1.3.2 Rectal and Renal Cancer

1.3.3 Lung Cancer

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

2.1 Global Subcutaneously Injected PD-L1 Antibody Market Size

2.2 Subcutaneously Injected PD-L1 Antibody Market Size by Region

2.2.1 Subcutaneously Injected PD-L1 Antibody Growth Rate by Region (2026-2032)

2.2.2 Subcutaneously Injected PD-L1 Antibody Market Share by Region (2026-2032)

2.3 Industry Trends

2.3.1 Market Top Trends

2.3.2 Market Use Cases

3.1 Subcutaneously Injected PD-L1 Antibody Revenue by Players (2026 & 2032)

3.2 Subcutaneously Injected PD-L1 Antibody Key Players Headquarters and Area Served

3.3 Key Players Subcutaneously Injected PD-L1 Antibody Product/Solution/Service

3.4 Date of Enter into Subcutaneously Injected PD-L1 Antibody Market

3.5 Mergers & Acquisitions, Expansion Plans

4.1 Global Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032)

4.2 Global Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032)

5.1 North America Subcutaneously Injected PD-L1 Antibody Market Forecast (2026-2032)

5.2 Subcutaneously Injected PD-L1 Antibody Key Players in North America

5.3 North America Subcutaneously Injected PD-L1 Antibody Market Size by Type

5.4 North America Subcutaneously Injected PD-L1 Antibody Market Size by Application

6.1 Europe Subcutaneously Injected PD-L1 Antibody Market Forecast (2026-2032)

6.2 Subcutaneously Injected PD-L1 Antibody Key Players in Europe

6.3 Europe Subcutaneously Injected PD-L1 Antibody Market Size by Type

6.4 Europe Subcutaneously Injected PD-L1 Antibody Market Size by Application

7.1 Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Forecast (2026-2032)

7.2 Subcutaneously Injected PD-L1 Antibody Key Players in Asia-Pacific

7.3 Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Type

7.4 Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Application

8.1 Latin America

8.1.1 Latin America Subcutaneously Injected PD-L1 Antibody Market Analysis

8.1.2 Key Players in Latin America

8.2 Middle East & Africa

8.2.1 Middle East & Africa Subcutaneously Injected PD-L1 Antibody Market Analysis

8.2.2 Key Players in Middle East & Africa

9.1 Roche

9.1.1 Roche Company Details

9.1.2 Roche Description and Business Overview

9.1.3 Roche Subcutaneously Injected PD-L1 Antibody Introduction

9.1.4 Roche Revenue in Subcutaneously Injected PD-L1 Antibody Business (2026 & 2032)

9.1.5 Roche Recent Development

9.2 Alphamab Oncology

9.2.1 Alphamab Oncology Company Details

9.2.2 Alphamab Oncology Description and Business Overview

9.2.3 Alphamab Oncology Subcutaneously Injected PD-L1 Antibody Introduction

9.2.4 Alphamab Oncology Revenue in Subcutaneously Injected PD-L1 Antibody Business (2026 & 2032)

9.2.5 Alphamab Oncology Recent Development

9.3 Bristol Myers Squibb

9.3.1 Bristol Myers Squibb Company Details

9.3.2 Bristol Myers Squibb Description and Business Overview

9.3.3 Bristol Myers Squibb Subcutaneously Injected PD-L1 Antibody Introduction

9.3.4 Bristol Myers Squibb Revenue in Subcutaneously Injected PD-L1 Antibody Business (2026 & 2032)

9.3.5 Bristol Myers Squibb Recent Development

10.1 Subcutaneously Injected PD-L1 Antibody Industry Trends

10.2 Subcutaneously Injected PD-L1 Antibody Market Drivers

10.3 Subcutaneously Injected PD-L1 Antibody Market Challenges

10.4 Subcutaneously Injected PD-L1 Antibody Market Restraints

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Disclaimer

12.3 Author Details

List of Tables

 Table 1. Global Subcutaneously Injected PD-L1 Antibody Market Size Growth Rate by Type (2026-2032) & (US$ Million)

 Table 2. Key Players of Add Hyaluronidase

 Table 3. Key Players of No Hyaluronidase

 Table 4. Global Subcutaneously Injected PD-L1 Antibody Market Size Growth by Application (2026-2032) & (US$ Million)

 Table 5. Global Subcutaneously Injected PD-L1 Antibody Market Size by Region (2026-2032) & (US$ Million)

 Table 6. Global Subcutaneously Injected PD-L1 Antibody Market Size by Region (2026-2032) & (US$ Million)

 Table 7. Global Subcutaneously Injected PD-L1 Antibody Market Share by Region (2026-2032)

 Table 8. Market Top Trends

 Table 9. Market Use Cases

 Table 10. Global Subcutaneously Injected PD-L1 Antibody Revenue by Players (2026 & 2032) & (US$ Million)

 Table 11. Global Subcutaneously Injected PD-L1 Antibody Market Share by Players (2026 & 2032)

 Table 12. Key Players Headquarters and Area Served

 Table 13. Key Players Subcutaneously Injected PD-L1 Antibody Product/Solution/Service

 Table 14. Date of Enter into Subcutaneously Injected PD-L1 Antibody Market

 Table 15. Mergers & Acquisitions, Expansion Plans

 Table 16. Global Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)

 Table 17. Global Subcutaneously Injected PD-L1 Antibody Market Size Share by Type (2026-2032)

 Table 18. Global Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)

 Table 19. Global Subcutaneously Injected PD-L1 Antibody Market Size Share by Application (2026-2032)

 Table 20. North America Key Players Subcutaneously Injected PD-L1 Antibody Revenue (2026 & 2032) & (US$ Million)

 Table 21. North America Key Players Subcutaneously Injected PD-L1 Antibody Market Share (2026 & 2032)

 Table 22. North America Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)

 Table 23. North America Subcutaneously Injected PD-L1 Antibody Market Share by Type (2026-2032)

 Table 24. North America Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)

 Table 25. North America Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)

 Table 26. Europe Key Players Subcutaneously Injected PD-L1 Antibody Revenue (2026 & 2032) & (US$ Million)

 Table 27. Europe Key Players Subcutaneously Injected PD-L1 Antibody Market Share (2026 & 2032)

 Table 28. Europe Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)

 Table 29. Europe Subcutaneously Injected PD-L1 Antibody Market Share by Type (2026-2032)

 Table 30. Europe Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)

 Table 31. Europe Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)

 Table 32. Asia-Pacific Key Players Subcutaneously Injected PD-L1 Antibody Revenue (2026 & 2032) & (US$ Million)

 Table 33. Asia-Pacific Key Players Subcutaneously Injected PD-L1 Antibody Market Share (2026 & 2032)

 Table 34. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)

 Table 35. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Share by Type (2026-2032)

 Table 36. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)

 Table 37. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)

 Table 38. Key Players in Latin America

 Table 39. Key Players in Middle East & Africa

 Table 40. Roche Company Details

 Table 41. Roche Description and Business Overview

 Table 42. Roche Subcutaneously Injected PD-L1 Antibody Product

 Table 43. Roche Revenue in Subcutaneously Injected PD-L1 Antibody Business: 2026 & 2032

 Table 44. Roche Recent Development

 Table 45. Alphamab Oncology Company Details

 Table 46. Alphamab Oncology Description and Business Overview

 Table 47. Alphamab Oncology Subcutaneously Injected PD-L1 Antibody Product

 Table 48. Alphamab Oncology Revenue in Subcutaneously Injected PD-L1 Antibody Business: 2026 & 2032

 Table 49. Alphamab Oncology Recent Development

 Table 50. Bristol Myers Squibb Company Details

 Table 51. Bristol Myers Squibb Description and Business Overview

 Table 52. Bristol Myers Squibb Subcutaneously Injected PD-L1 Antibody Product

 Table 53. Bristol Myers Squibb Revenue in Subcutaneously Injected PD-L1 Antibody Business: 2026 & 2032

 Table 54. Bristol Myers Squibb Recent Development

 Table 55. Subcutaneously Injected PD-L1 Antibody Market Trends

 Table 56. Subcutaneously Injected PD-L1 Antibody Market Drivers

 Table 57. Subcutaneously Injected PD-L1 Antibody Market Challenges

 Table 58. Subcutaneously Injected PD-L1 Antibody Market Restraints

 Table 59. Research Programs/Design for This Report

 Table 60. Key Data Information from Secondary Sources

 Table 61. Key Data Information from Primary Sources

List of Figures

 Figure 1. Global Subcutaneously Injected PD-L1 Antibody Market Share by Type in 2026 & 2032

 Figure 2. Add Hyaluronidase Features

 Figure 3. No Hyaluronidase Features

 Figure 4. Global Subcutaneously Injected PD-L1 Antibody Market Share by Application in 2026 & 2032

 Figure 5. Rectal and Renal Cancer Case Studies

 Figure 6. Lung Cancer Case Studies

 Figure 7. Other Case Studies

 Figure 8. Subcutaneously Injected PD-L1 Antibody Report Years Considered

 Figure 9. Global Subcutaneously Injected PD-L1 Antibody Market Size and Growth Rate 2026-2032 (US$ Million)

 Figure 10. Global Subcutaneously Injected PD-L1 Antibody Market Share by Region (2026-2032)

 Figure 11. Global Subcutaneously Injected PD-L1 Antibody Market Size Market Share by Type (2026-2032)

 Figure 12. North America Subcutaneously Injected PD-L1 Antibody Market Size 2026-2032 (US$ Million)

 Figure 13. Europe Subcutaneously Injected PD-L1 Antibody Market Size 2026-2032 (US$ Million)

 Figure 14. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size 2026-2032 (US$ Million)

 Figure 15. Subcutaneously Injected PD-L1 Antibody Market Size in Latin America (2026-2032) & (US$ Million)

 Figure 16. Subcutaneously Injected PD-L1 Antibody Market Size in Middle East & Africa (2026-2032) & (US$ Million)

 Figure 17. Bottom-up and Top-down Approaches for This Report

 Figure 18. Data Triangulation

 Figure 19. Key Executives Interviewed